Madurahydroxylactone, an Inhibitor of Staphylococcus aureus FtsZ from Nonomuraea sp. AN100570
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
FtsZ, a bacterial cell-division protein, is an attractive antibacterial target. In the screening for an inhibitor of Staphylococcus aureus FtsZ, madurahydroxylactone (1) and its related derivatives 2-5 were isolated from Nonomuraea sp. AN100570. Compound 1 inhibited S. aureus FtsZ with an IC50 of 53.4 μM and showed potent antibacterial activity against S. aureus and MRSA with an MIC of 1 μg/ml, whereas 2-5 were weak or inactive. Importantly, 1 induced cell elongation in the cell division phenotype assay, whereas 2-5 did not. It indicates that 1 exhibits its potent antibacterial activity via inhibition of FtsZ, and the hydroxyl group and hydroxylactone ring of 1 are critical for the activity. Thus, madurahydroxylactone is a new type of inhibitor of FtsZ.
Abstract
FtsZ, a bacterial cell-division protein, is an attractive antibacterial target. In the screening for an inhibitor of Staphylococcus aureus FtsZ, madurahydroxylactone (1) and its related derivatives 2-5 were isolated from Nonomuraea sp. AN100570. Compound 1 inhibited S. aureus FtsZ with an IC50 of 53.4 μM and showed potent antibacterial activity against S. aureus and MRSA with an MIC of 1 μg/ml, whereas 2-5 were weak or inactive. Importantly, 1 induced cell elongation in the cell division phenotype assay, whereas 2-5 did not. It indicates that 1 exhibits its potent antibacterial activity via inhibition of FtsZ, and the hydroxyl group and hydroxylactone ring of 1 are critical for the activity. Thus, madurahydroxylactone is a new type of inhibitor of FtsZ.
참고문헌 (20)
- Klein E, "Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005", Emerg. Infect. Dis, 13, pp.1840~1846 (2007)
- Levy SB, "Antibacterial resistance worldwide:causes, challenges and responses", Nat. Med, 10, pp.S122~S129 (2004)
- Brown ED, "Antibacterial drug discovery in the resistance era", Nature, 529, pp.336~343 (2016)
- Butler MS, "Screening strategies to identify new antibiotics", Curr. Drug Targets, 13, pp.373~387 (2012)
- Lock RL, "Cell-division inhibitors: new insights for future antibiotics", Nat. Rev. Drug Discov, 7, pp.324~338 (2008)
- Vollmer W., "The prokaryotic cytoskeleton: a putative target for inhibitors and antibiotics?", Appl. Microbiol. Biotechnol, 73, pp.37~47 (2006)
- Kapoor S, "Targeting FtsZ for antibacterial therapy: a promising avenue", Expert Opin. Ther. Targets, 13, pp.1037~1051 (2009)
- Haydon DJ, "An inhibitor of FtsZ with potent and selective anti-staphylococcal activity", Science, 321, pp.1673~1675 (2008)
- Sun N, "Rational design of berberine-based FtsZ inhibitors with broad-spectrum antibacterial activity", PLoS One, 9, pp.e97514~ (2014)
- Wang J, "Discovery of a small molecule that inhibits cell division by blocking FtsZ, a novel therapeutic target of antibiotics", J. Biol. Chem, 278, pp.44424~44428 (2003)
- Stokes NR, "Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay", J. Biol. Chem, 280, pp.39709~39715 (2005)
- Domadia PN, "Berberine targets assembly of Escherichia coli c ell division protein FtsZ", Biochemistry, 47, pp.3225~3234 (2008)
- Beuria TK, "Sanguinarine blocks cytokinesis in bacteria by inhibiting FtsZ assembly and bundling", Biochemistry, 44, pp.16584~16593 (2005)
- Park YS, "Synthesis of (-)-viriditoxin: a 6,6’-binaphthopyran-2-one that targets the bacterial cell division protein FtsZ", Angew. Chem. Int. Ed. Engl, 50, pp.3730~3733 (2011)
- Stokes NR, "An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacy", Antimicrob. Agents Chemother, 57, pp.317~325 (2013)
- Fleck WF, "Fermentation, isolation, and biological activity of maduramycin:a new antibiotic from Actinomadura rubra", Z. Allg. Mikrobiol, 18, pp.389~398 (1978)
- Marchand C, "Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1integrase and RNase H", Antimicrob. Agents Chemother, 52, pp.361~364 (2008)
- Heinisch L, "Semisynthetic derivatives of madura hydroxylactone and their antibacterial activities", J. Antibiot. (Tokyo), 52, pp.1029~1041 (1999)
- Strauss DG, "Butylmaduramycin, a new antibiotic from Actinomadura rubra", J. Basic Microbiol, 26, pp.169~172 (1986)
- Zheng CJ, "Vinaxanthone, a new FabI inhibitor from Penicillium sp", J. Antimicrob. Chemother, 63, pp.949~953 (2009)